An immune‐related seven‐lncRNA signature for head and neck squamous cell carcinoma. (3rd March 2021)

• Record Type: Journal Article
• Authors: Chen, Yue; Luo, Tian‐Qi; Xu, Si‐Si; Chen, Chun‐Yan; Sun, Ying; Lin, Li; Mao, Yan‐Ping
• Is Part Of: Cancer medicine. Volume 10:Number 7(2021)
• Page Start: 2268
• Page End: 2285
• Publication Date: 2021-03-03
• Subjects: head and neck squamous cell carcinoma -- immune -- lncRNA -- tumor microenvironment; 616.994005
• DOI: 10.1002/cam4.3756
• Languages: English
• ISSNs: 2045-7634

Abstract

Abstract: In this study, we developed a long noncoding RNA (lncRNA)‐based prognostic signature for stratification of patients with head a nd neck squamous cell carcinoma (HNSCC). In total, 493 HNSCC samples obtained from the Cancer Genome Atlas database were divided into training and testing cohorts (3:2 ratio). We identified 3913 immune‐related lncRNAs in the HNSCC training cohort by Pearson correlation analysis; only seven were independently associated with overall survival and were used to develop an immune‐related lncRNA prognostic signature (IRLPS) grouping of HNSCC patients into high‐ and low‐IRLPS subgroups. Univariate and multivariate Cox analyses revealed that low‐IRLPS patients had a better prognosis in all the cohorts, which was retained after stratification by sex, grade, and HPV status. Although the TNM stage was also an independent prognostic factor, the IRLPS had a better discriminability with higher AUC at the 3‐ and 5‐year follow‐ups in all cohorts. Low‐IRLPS samples had more immune cell infiltration and were enriched in immune‐related pathways, while high‐ IRLPS samples were enriched in metabolic pathways. A nomogram constructed including age, TNM stage, and IRLPS showed good calibration. Thus, IRLPS improves the prognostic prediction and also distinguishes different tumor microenvironment (TME) in HNSCC patients. Abstract : We developed an immune‐related lncRNA signature for head and neck squamous cell carcinoma (HNSCC) patients, which could improve the prognostic prediction and distinguish different tumor microenvironments (TMEs) in HNSCC patients.